As a Chronically Ill Patient, Lifting COVID-19 Restrictions Scares Me

As parts of the world begin to partially open up again amid the COVID-19 pandemic, I can’t help but feel fearful and anxious. Those of us with chronic respiratory illnesses like idiopathic pulmonary fibrosis (IPF) must regularly take precautions to avoid getting sick throughout the entire year. However, the…

Rates of hospitalization and in-hospital mortality dropped significantly for people with idiopathic pulmonary fibrosis (IPF) in the U.S. between 2006 and 2016, and hospitalizations were most common in colder months, an analyses of disease trends found. The study, “Trends and…

I have always advocated for good mental health and promoted the importance of self-care. I preach regularly about this to friends, family, colleagues, and other patients with idiopathic pulmonary fibrosis (IPF). Since being diagnosed with this life-threatening lung disease, my physical health has been a priority. I do…

Single lung transplant patients with idiopathic pulmonary fibrosis (IPF) have a higher risk of developing lung cancer, according to a recent study — and these cancers are more likely to be diagnosed at an advanced stage and carry a worse prognosis. Thus, the researchers recommend prioritizing people with IPF…

A cell therapy approach based on transplanting a type of lung cells called type II alveolar cells halted scarring (fibrosis) in a rat model of idiopathic pulmonary fibrosis (IPF) with established disease. This anti-fibrotic effect was associated with a drop in lung levels of several fibrotic markers, the researchers said.

As I sat in my mom’s hospital room on the day of her long-awaited discharge, I felt like we were bringing home a very fragile adult baby. Her body had been through a series of assaults starting with an acute exacerbation of IPF and ending with a double-lung transplant.

New preclinical data support MRG-229, an investigative next-generation treatment for idiopathic pulmonary fibrosis (IPF), as safe and effective, miRagen reported. “We believe this body of evidence supports further development of MRG-229 as a potentially differentiated approach for the treatment of IPF,” William S. Marshall, PhD, the company’s president and CEO, said in…